• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Stability of human recombinant epoetin alfa in commonly used neonatal intravenous solutions.

作者信息

Ohls R K, Christensen R D

机构信息

Department of Pediatrics, School of Medicine, University of New Mexico, Albuquerque 87131, USA.

出版信息

Ann Pharmacother. 1996 May;30(5):466-8. doi: 10.1177/106002809603000505.

DOI:10.1177/106002809603000505
PMID:8740324
Abstract

OBJECTIVE

To measure epoetin alfa concentrations after adding it to a variety of commonly used neonatal intravenous fluids to determine the stability of epoetin alfa over time.

DESIGN

Epoetin alfa was added to the following fluids: sterile water; NaCl 0.9%; dextrose 10% in water; dextrose 10% with albumin at concentrations of 0.01%, 0.05%, and 0.1%; and total parenteral nutrition solution containing either 0.5% or 2.25% amino acids. The fluid was administered through intravenous tubing, a T-connector, and catheter, and samples were collected at 0, 2, 4, 8, and 24 hours.

MAIN OUTCOME MEASURES

Epoetin alfa concentrations were compared with the measured original preinfusion concentration and recorded as the percentage recovered.

RESULTS

Concentrations declined significantly in all fluids containing less than 0.05% protein, but remained stable over 24 hours in fluids containing 0.05% or more protein.

CONCLUSIONS

We conclude that epoetin alfa should be mixed in intravenous fluids containing at least 0.05% protein.

摘要

相似文献

1
Stability of human recombinant epoetin alfa in commonly used neonatal intravenous solutions.
Ann Pharmacother. 1996 May;30(5):466-8. doi: 10.1177/106002809603000505.
2
Stability of filgrastim and epoetin alfa in a system designed for enteral administration in neonates.在一种专为新生儿肠内给药设计的系统中,非格司亭和促红细胞生成素α的稳定性。
Ann Pharmacother. 2000 Nov;34(11):1257-61. doi: 10.1345/aph.10105.
3
Factors associated with successful epoetin alfa therapy in premature infants.与早产儿促红细胞生成素α治疗成功相关的因素。
Ann Pharmacother. 2000 Apr;34(4):433-9. doi: 10.1345/aph.19169.
4
Stability, potency, and preservative effectiveness of epoetin alfa after addition of a bacteriostatic diluent.
Am J Hosp Pharm. 1992 Jun;49(6):1455-8.
5
Comment: Epoetin alfa loss with NaCl 0.9% dilution.评论:促红细胞生成素α在0.9%氯化钠稀释液中的损失情况。
Ann Pharmacother. 1996 Dec;30(12):1501-2. doi: 10.1177/106002809603001232.
6
Stability and biological activity of epoietin beta in parenteral nutrition solutions.促红细胞生成素β在肠外营养溶液中的稳定性和生物活性。
Biol Neonate. 2002;81(3):158-62. doi: 10.1159/000051528.
7
Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis.静脉注射与皮下注射促红细胞生成素α对透析患者血细胞比容稳定性的影响:一项事后分析
Clin Nephrol. 1999 Jun;51(6):367-72.
8
Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.危重症患者每周一次皮下注射促红细胞生成素α的药代动力学和药效学:一项随机、双盲、安慰剂对照试验的结果
Crit Care Med. 2006 Jun;34(6):1661-7. doi: 10.1097/01.CCM.0000217919.22155.85.
9
What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?在临床试验之外,从阿法依泊汀转换为达比泊汀时的实际转换剂量是多少?
Nephrology (Carlton). 2004 Aug;9(4):223-8. doi: 10.1111/j.1440-1797.2004.00261.x.
10
An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.一项在长期护理环境中用重组人促红细胞生成素治疗慢性肾脏病贫血的开放性、随机、多中心、对照研究。
J Am Med Dir Assoc. 2012 Mar;13(3):244-8. doi: 10.1016/j.jamda.2010.09.009. Epub 2010 Nov 11.

引用本文的文献

1
Y-site compatibility of medications with parenteral nutrition.药物与肠外营养的Y型接口兼容性
J Pediatr Pharmacol Ther. 2009 Jan;14(1):48-56. doi: 10.5863/1551-6776-14.1.48.
2
Y-site compatibility of medications with parenteral nutrition.药物与肠外营养的Y型接口兼容性
J Pediatr Pharmacol Ther. 2007 Jan;12(1):53-9. doi: 10.5863/1551-6776-12.1.53.
3
Erythropoietin acts as a trophic factor in neonatal rat intestine.促红细胞生成素在新生大鼠肠道中起营养因子的作用。
Gut. 2001 Aug;49(2):182-9. doi: 10.1136/gut.49.2.182.